5-YEAR SURVEY OF METHOTREXATE, CYCLOPHOSPHAMIDE (ENDOXAN), AND VINCRISTINE (MEV) THERAPY FOR ADVANCED NON-HODGKINS LYMPHOMAS

  • 1 January 1978
    • journal article
    • research article
    • Vol. 62  (8) , 1193-1197
Abstract
Five courses of a combination chemotherapy regimen with MEV were given to 64 patients, 37 with lymphocytic lymphoma (LL) and 27 with histiocytic lymphoma (HL). Of the 37 patients with LL, 18 (48%) achieved a complete remission (CR): 12 of these 18 patients have been in CR for 20-58 mo. Among the complete responders only 2 died. Of the 27 patients with HL, 22 (81%) achieved CR and 12 of these patients are still in CR. Of the complete responders, 10 have been relapse-free for 24-70 mo. and 5 have been relapse-free for 60 mo. Clinical and hematologic tolerance was such that the interval between each course had to be prolonged in only 3 of the 64 patients and, with the exception of vincristine, the dosages were not reduced.